Barrett's esophagus

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Retrieved on: 
화요일, 5월 14, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Medical Devices, Research, Surgery, Science, Stomach, MPH, DDW, ASGE, Organization, Meta-analysis, Treatment, University, Woman, Esophageal cancer, FACG, Barrett's esophagus, FACP, FACS, Division, GI, Abstract, Risk factor, Malignancy, Systematic review, Esophagus, Hepatology, Vaccine

Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis

Key Points: 
  • Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis
    Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
    Title: The Tissue Systems Pathology Test Provides Clinically Actionable Risk-Stratification in Patients with Barrett’s Esophagus: A Multicenter U.S. Clinical Experience
    Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
    For more information on the above abstracts and the TissueCypher test, visit Castle at booth 3737; a complete list of Castle’s activities at DDW 2024 can be found at https://info.castlebiosciences.com/ddw2024 .
  • Key events include the following:
    Panel discussion to include: Emmanuel Gorospe, M.D., MPH, FACP, FACG, FASGE, GI medical director at Castle Biosciences; Dan Lister, M.D., FACS, FAFS, surgeon and director of the Arkansas Heartburn Treatment Center, and co-founder and president elect of the American Foregut Society; Dr. Farhan Quader, M.D., interventional gastroenterologist at NorthShore University Hospital in Chicago; Sarah Enslin, PA-C, Division of Gastroenterology and Hepatology at the University of Rochester Medical Center Rochester in New York
    Additionally, Castle is collaborating with several organizations, including the ASGE, Esophageal Cancer Action Network, American Muslim Gastroenterologist Network, American Foregut Society and Women in Endoscopy on various educational and networking events taking place throughout the meeting.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Retrieved on: 
목요일, 5월 2, 2024
Johns Hopkins University, University, Mayo Clinic, Cancer, SOS, American College, Case Western Reserve University, AUC, ACG, Esophageal cancer, Prevalence, Methylation, Risk, Barrett's esophagus, Cleveland Clinic, American Journal, Lucid, Adenocarcinoma, National Cancer Institute, NPV, NGS, University of North Carolina, Gold, Detection, EGD, Patient, Research report, NCI, PPV, Medicare, Manuscript, GERD, Guideline, Gastroesophageal reflux disease, Medical imaging

NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D., was funded through the NCI's Barrett's Esophagus Translational Research Network (BETRNet), and included renowned investigators from leading academic medical centers, including Case Western Reserve University, Mayo Clinic, Johns Hopkins University, Washington University in St. Louis, University of North Carolina, and Cleveland Clinic. EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD). The manuscript, entitled Multicenter, Prospective Trial of Non-Endoscopic Biomarker-Driven Detection of Barrett's Esophagus And Esophageal Adenocarcinoma, was published in the American Journal of Gastroenterology, the leading clinical journal covering gastroenterology published on behalf of the American College of Gastroenterology (ACG).

Key Points: 
  • EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD).
  • Dr. Aklog concluded, "The publication of the BETRNet study is the culmination of a period of rapid expansion of EsoGuard's clinical evidence base.
  • It represents the second peer-reviewed, and third overall, clinical validation study demonstrating consistently excellent EsoGuard performance.
  • Soon to be released data from a fourth such clinical validation study tells the same story.

Implantica's RefluxStop™ is now available in seven hospitals in Spain adding two new centers of excellence

Retrieved on: 
목요일, 5월 2, 2024
Certification, PMID, Cancer, Esophagitis, Surgeon, Dysphagia, Patient, Prevalence, Barrett's esophagus, GERD

), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.
  • More patients in Spain will have access to the innovative RefluxStop™ procedure now, given that a total of seven anti-reflux centers of excellence in the country regularly perform the procedure.
  • "It's a new day we've long awaited in the world of surgical GERD treatment," says Dra.
  • She continues, "I'm pleased to see that RefluxStop does not encircle the food passageway and restores the body's natural physiology.

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Retrieved on: 
수요일, 3월 20, 2024
Lucid, Washington Convention Center, Walter, GERD, Esophagus, Cancer, Abstract, DDW, Barrett's esophagus, Assessment, Annual general meeting

NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024—the world's premier meeting for digestive disease professionals.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024 —the world's premier meeting for digestive disease professionals.
  • "We are excited that our technologies will be prominently featured in multiple presentations at this year's DDW conference," said Suman Verma, M.D., Ph.D., Lucid Senior Vice President, and Chief Scientific Officer.
  • DDW 2024 will be held at the Walter E. Washington Convention Center in Washington, D.C., May 18 to 24, 2024.
  • Details on the time and location of the presentations will be provided prior to the conference.

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

Retrieved on: 
화요일, 2월 20, 2024
Marie Cassidy, Prophase, Barrett's esophagus, Patent, Gastroenterology, LDT, Risk, Cancer, GI, Mayo Clinic, The Wall Street Journal, Clinical professor, Patient, Carcinogenesis, Clinical trial, Genomics, Esophageal cancer, Plague

This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.

Key Points: 
  • This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
  • If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
  • Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
  • - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
수요일, 3월 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

A Match Made for Comfort: Barrett Distribution Centers Partners with #1 Pillow Maker COOP Sleep Goods

Retrieved on: 
수요일, 1월 24, 2024
Online Retail, Retail, Consumer, Logistics, Supply Chain Management, Home Goods, Transport, Baby, Maternity, E-commerce, Sleep, COOP, Partnership, Bailey, Operation, Mother, DTC, Barrett's esophagus, NetSuite, 3PL, Poultry farming

Today, Barrett Distribution Centers , a pioneering name in third-party logistics (3PL) since 1941, is thrilled to announce its new partnership with the rapidly growing, direct-to-consumer (DTC) brand COOP Sleep Goods.

Key Points: 
  • Today, Barrett Distribution Centers , a pioneering name in third-party logistics (3PL) since 1941, is thrilled to announce its new partnership with the rapidly growing, direct-to-consumer (DTC) brand COOP Sleep Goods.
  • COOP will also be taking advantage of the robust Managed Transportation solution at Barrett.
  • Mark Healy, Vice President of Customer Solutions , shared his perspective: “We are thrilled to be the chosen partner of COOP Sleep Goods.
  • This unique combination enables them to efficiently handle major demands while maintaining a deep commitment to their partners' success, a balance that's crucial for COOP Sleep Goods and other growing brands.

EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis

Retrieved on: 
화요일, 12월 5, 2023
Patient, Hospital, Dysphagia, Heartburn, Eosinophilic esophagitis, Drinking, Barrett's esophagus, Extrapyramidal system, Conditional sentence, Esophagus, Fungal infection, Eosinophil, Safety, Vomiting, Esophageal cancer, Candidiasis

The ACESO study is a randomized, placebo-controlled, double-blind Phase II study to evaluate the efficacy, tolerability and safety of ESO-101 in patients with active eosinophilic esophagitis (EoE).

Key Points: 
  • The ACESO study is a randomized, placebo-controlled, double-blind Phase II study to evaluate the efficacy, tolerability and safety of ESO-101 in patients with active eosinophilic esophagitis (EoE).
  • "The ACESO study represents an important milestone in the development of our unique application platform for the treatment of esophageal diseases.
  • Following the successful results of this Phase II study, we now plan to initiate a Phase III program in eosinophilic esophagitis,” said Isabelle Racamier, CEO of EsoCap.
  • The detailed results from the ACESO study, including secondary endpoint data, will be submitted for presentation at a future scientific conference.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Retrieved on: 
화요일, 12월 12, 2023
Identification, Esophageal, Biomedical Research, Risk, Esophagus, Patient, Data analysis, Extrapyramidal system, Triage, Barrett's esophagus, Physician, Archive, Registry, Publication, Medical imaging, Nursing, Lucid, Endoscopy

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—the first peer-reviewed publications demonstrating real-world clinical utility of Lucid's EsoGuard® Esophageal DNA test to detect esophageal precancer.

Key Points: 
  • Real-World Experience and Clinical Utility of EsoGuard® – Interim Data from the Lucid Registry .
  • Interim analysis of 409 of 517 enrolled patients with complete clinical utility data in the PREVENT and PREVENT-FF registries of patients undergoing EsoGuard testing by Lucid personnel.
  • "These clinical utility studies, encompassing over 1,000 patients, clearly demonstrate that prescribing physicians are properly leveraging EsoGuard results to guide their medical decision making," said Victoria T. Lee, M.D.
  • "These outstanding clinical utility results complement existing clinical validity data on EsoGuard's unprecedented precancer detection performance.

PREVISE FUELS GROWTH OF ITS BARRETT'S ESOPHAGUS RISK STRATIFICATION TEST WITH A COMPETITIVE $1.8M SBIR GRANT

Retrieved on: 
목요일, 10월 12, 2023
Physician, Biomarker, Johns Hopkins School of Medicine, Barrett's esophagus, Risk, Kidney, Methylation, Health, NIDDK, Cancer, Gastroenterology, Esophageal cancer, Bangladesh Technical Education Board, Digestive, National Institute of Diabetes and Digestive and Kidney Diseases, Patient, NIH, Small Business Innovation Research, SBIR, Pharmaceutical industry

BALTIMORE, Oct. 12, 2023 /PRNewswire/ -- Previse, maker of Esopredict, a clinically available test that analyzes methylation of biomarkers to assess the risk of esophageal cancer developing in patients with Barrett's esophagus and currently provides GI physicians with results within one week, was awarded a prestigious and highly competitive $1.8M Direct to Phase II SBIR (Small Business Innovation Research) grant by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

Key Points: 
  • Esopredict™, Previse's Flagship Product, Awarded NIH Direct to Phase II SBIR Grant to Drive Further Studies of Commercially Available Barrett's Esophagus Prognostic Test.
  • Securing the SBIR grant for this project involved Previse collaborating with investigators at Johns Hopkins University School of Medicine to submit intensive research and commercialization plans to the NIH, outlining the path Previse is taking to accelerate the adoption of the Esopredict test.
  • Esopredict is a game-changing assay rooted in highly accurate methylation-based analysis, which empowers gastroenterologists to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett's esophagus.
  • Previse CEO Daniel Lunz said: "This substantial grant awarded by the NIH underlines the potential impact of Previse's Esopredict assay and methylation technology.